There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Henry Schein (HSIC – Research Report) and DocGo (DCGO – Research Report) with bullish sentiments.
Henry Schein (HSIC)
In a report issued on November 27, Jonathan Block from Stifel Nicolaus maintained a Buy rating on Henry Schein, with a price target of $75.00. The company’s shares closed last Wednesday at $66.66.
According to TipRanks.com, Block is a 4-star analyst with an average return of
Henry Schein has an analyst consensus of Moderate Buy, with a price target consensus of $76.17, implying a 13.8% upside from current levels. In a report issued on November 14, Barrington also maintained a Buy rating on the stock with a $82.00 price target.
See the top stocks recommended by analysts >>
DocGo (DCGO)
In a report issued on November 27, David Grossman from Stifel Nicolaus maintained a Buy rating on DocGo, with a price target of $12.00. The company’s shares closed last Wednesday at $5.52, close to its 52-week low of $4.88.
According to TipRanks.com, Grossman is ranked #383 out of 8725 analysts.
Currently, the analyst consensus on DocGo is a Strong Buy with an average price target of $12.40, which is an 117.5% upside from current levels. In a report issued on November 20, Northland Securities also maintained a Buy rating on the stock with a $16.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HSIC:
- Henry Schein receives deficiency notice from Nasdaq
- JPMorgan medical distribution analyst holds an analyst/industry conference call
- Henry Schein price target lowered to $82 from $90 at Barrington
- Henry Schein price target lowered to $78 from $84 at Piper Sandler
- Henry Schein price target lowered to $76 from $82 at Baird
